Vir Biotechnology, Inc. (VIR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$11.02-6.37%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · VIR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
In oncology, VIR-5500 achieved proof of concept and received FDA Fast Track designation, supporting our plans with Astellas to advance the program into pivotal trials next year.
Stated in 3 of 4 supplied quarters. Management reported: “In oncology, VIR-5500 achieved proof of concept and received FDA Fast Track designation, supporting our plans with Astellas to advance the program into pivotal trials next year.” “The Company expects multiple pivotal trials to begin in 2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“In oncology, VIR-5500 achieved proof of concept and received FDA Fast Track designation, supporting our plans with Astellas to advance the program into pivotal trials next year.”
““Beyond CHD, we remain focused on rapid execution of our joint clinical program with Astellas in prostate cancer and have initiated monotherapy and combination therapy dose-expansion cohorts in our V…”
“The closing of our collaboration with Astellas in April has ignited the next stage of development work, bolstering our ability to move faster and think bigger together,” said Marianne De Backer, Chie…”
“We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the significant unmet need for patients with a therapy that can drive hepatitis delta virus to unde…
Stated in 3 of 4 supplied quarters. Management reported: ““We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the significant unmet need for patients with a therapy that can drive hepatitis delta virus to undetectable.” “• Topline data from the pivotal ECLIPSE 1 trial are expected in the fourth quarter of 2026.”
““We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the significant unmet need for patients with a therapy that can drive hepatitis delta virus to unde…”
“Document Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and to…”
““We also announced promising updated Phase 2 data on our combination regimen in CHD and will be presenting complete Week 96 data at the EASL Congress later this month.”
2026 Financial Guidance Based on our current operating plans, the Company continues to expect its cash, cash equivalents and investments to fund operations into the second half of 2028.
Stated in 3 of 4 supplied quarters. Management reported: “2026 Financial Guidance Based on our current operating plans, the Company continues to expect its cash, cash equivalents and investments to fund operations into the second half of 2028.” “ET / 1:30 p.m.”
“2026 Financial Guidance Based on our current operating plans, the Company continues to expect its cash, cash equivalents and investments to fund operations into the second half of 2028.”
“20 26 Financial Guidance Based on our current operating plans, including the net effects of the Astellas global collaboration, the Company expects its cash, cash equivalents and investments to fund o…”
“20 26 Financial Guidance Based on our current operating plans, including the net effects of the Astellas global collaboration, the Astellas equity investment and the completion of the recent equity f…”
• The Company announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN ® dual-masked TCE development candidates targeting selected solid tumor-associa…
Stated in 1 of 4 supplied quarters. Management reported: “• The Company announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN ® dual-masked TCE development candidates targeting selected solid tumor-associated antigens.” “Vir Biotechnology will be eligible to receive up to $135 million in total upfront and near-term preclinical milestone payments, consisting of $90 million in upfront consideration, which includes $65 million in cash and a $25 million equity investment at a 30% premium, and up to $45 million in potential near-term preclinical milestones.”
“• The Company announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN ® dual-masked TCE development candidates targeting selected solid tumor-associa…”
Continue disciplined capital allocation and resource management to support pipeline advancement and financial sustainability.
Over the trailing year it converted 1.00x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
15 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.